Physician profile
Amrish K Patel
NPI 1952326225
$4,070.63
in general payments reported to CMS, 2019-2025
24 companies · $433 in 2025
The $433 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $764 · 2020: $376 · 2021: $771 · 2022: $609 · 2023: $636 · 2024: $482 · 2025: $433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,529 · Consulting Fee: $22.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,528.55 |
| Consulting Fee | $22.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,366.49 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $476.36 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $468.53 | 2019-2024 | |
| Genentech USA, INC. | $396.19 | 2019-2023 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $225.45 | 2020-2025 | Hyqvia |
| Sunovion Pharmaceuticals INC. | $205.27 | 2019 | |
| Alk-Abello, INC | $174.44 | 2020-2023 | Odactra, Ragwitek, Grastek |
| Amgen INC. | $143.08 | 2022-2025 | Tezspire |
| Pharming Healthcare, INC. | $121.82 | 2019-2025 | Ruconest |
| Regeneron Healthcare Solutions, INC. | $95.40 | 2021-2024 | Dupixent |
| Genzyme Corporation | $61.92 | 2021-2023 | |
| Kaleo, INC. | $51.83 | 2020-2021 | |
| Jubilant Hollisterstier LLC | $37.28 | 2024 | |
| Optinose US, INC. | $36.78 | 2021-2022 | |
| Covis Pharma Gmbh | $31.76 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.07 | 2020-2021 | |
| Adma Biomanufacturing LLC | $22.82 | 2025 | |
| Grifols USA, LLC | $22.54 | 2020 | |
| Leo Pharma INC. | $18.61 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $18.03 | 2021 | |
| Shire North American Group INC | $16.75 | 2019 | |
| Csl Behring | $16.49 | 2020 | |
| Abbvie INC. | $16.05 | 2021 | |
| Uswm, LLC | $15.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amrish Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.